Daniel Forche News Today

GenesisCare and PreludeDx™ Partner to Provide Access to Ground-Breaking Precision Medicine Test for Women With Early-Stage Breast Cancer on February 23 2021 9:00 PM SYDNEY & LAGUNA HILLS, Calif.--(BUSINESS WIRE)--#breastcancerawareness--GenesisCare, a leading provider of integrated cancer care globally, and Prelude Corporation (PreludeDx TM), a leader in molecular diagnostics and precision medicine, today announced a new strategic partnership aimed at increasing access to personalized breast ...

Share this article Share this article LAGUNA HILLS, Calif., Dec. 15, 2020 /PRNewswire/ -- Prelude Corporation (PreludeDxä), a leader in molecular diagnostics and precision medicine for early stage breast cancer, presented clinical outcomes data last week at the San Antonio Breast Cancer Symposium (SABCS) that further validates the DCISionRT® test results of an independent study by Kaiser Permanente Northwest published earlier this year in Clinical Cancer Research.  DCISionRT is a biologic ...